Table 2.

Preclinical in vivo studies of IGF-IR inhibitors by tumor model and treatment

Tumor typeCell lineTreatment
EffectCitations
IGF-IR inhibitorOther agent
Single agent
Breast cancerMCF-7NVP-ADW742, XL820, IMC-A12, h7C10, and cp-751,871Active(60, 97, 106, 115)
Breast cancer, HER2+ trastuzumab resistantSKBR3-Her10IMC-A12Active(125)
Colorectal cancerColo-205, GEO, SW620, NCI-H322M, HT29XL820, OSI906, IMC-A12, R1507 and cp-751,871Active(24, 97, 113, 115)
NSCLCA549, NCI-H322MXL820, OSI906, R1507, and h7C10Active(100, 106, 115, 126)
Prostate cancerLuCaP35, LuCaP 23.1IMC-A12Active(127)
Ewing sarcomaTC-71, SK-ES-1 and SK-NEP-1AMG-479, NVP-AEW541, and NVP-ADW742(23, 39, 41, 92, 93)
Pediatric sarcomas/other tumorsnsBMS-536924, CP-751871Active(76, 84, 103, 105)
Pancreatic cancerBxPC-3IMC-A12, AVE-1642, AMG-479Active(97, 101, 103)
Drug combinations
NSCLCA549MK-0646VinorelbineSynergism(106)
NSCLCA549h7C10CetuximabSynergism(106)
Ovarian cancerNSPQIPErlotinibSynergism(128)
Breast cancer, HER2+ trastuzumab resistantSKBR3IR-α (murine antibody)LapatinibSynergism(46)
Breast cancerBT474NVP-ADW541TrastuzumabSynergism(119)
Breast cancer ER+MCF-7h7C10TamoxifenLess than additive effect(106)
Pancreatic cancerBxPC-3, MiaPaCaAMG-479, MK-0646Gemcitabine, erlotinib, panitumumabSynergism(101, 103)
Head and NeckTU159IMC-A12CetuximabSynergism(98)
Colorectal cancerGEO, HT29OSI-906ErlotinibSynergism(50)
Pediatric sarcomasEW5,ES2, ES8, OS1, OS9, Rh18CP-751871RapamycinSynergism(76)
OtherSeveralSeveral antibodies, NVP-ADW742Melphalan, vinorelbine, docetaxel, adryamicin, 5-fluoruracil, doxorubicin, and gemcitabineSynergism(54, 90, 96, 129, 130)
Combination with radiation
NSCLCH460IMC-A12RadiationSynergism(131)